Pathway activation strength is a novel independent prognostic biomarker for cetuximab sensitivity in colorectal cancer patients

Human Genome Variation

Volumn 2, Issue 1, 2015, Pages

  Zhu, Qingsong ^a   Izumchenko, Evgeny ^b   Aliper, Alexander M ^a,c,d   Makarev, Evgeny ^a   Paz, Keren ^e   Buzdin, Anton A ^c,d,f   Zhavoronkov, Alex A ^a,c,d   Sidransky, David ^b  

^a Insilico Medicine Inc   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Clinical Center of Pediatric Hematology Oncology and Immunology   (Russian Federation)

^d Pathway Pharmaceuticals Limited   (Hong Kong)

^e Champions Oncology Inc   (United States)

^f SHEMYAKIN OVCHINNIKOV INSTITUTE OF BIOORGANIC CHEMISTRY   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84943400336     PISSN: None     EISSN: 2054345X     Source Type: Journal    
DOI: 10.1038/hgv.2015.9     Document Type: Article

References (62)

1. Cancer Facts and Statistics. More information is available online: http://www. cancer.org/research/cancerfactsstatistics/. The American Cancer Society 2014.
2. Sobrero AF, Maurel J, Fehrenbacher L, Scheithauer W, Abubakr YA, Lutz MP et al. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxa-liplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26: 2311–2319.
3. Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007; 25: 1658–1664.
4. Jonker DJ, O'Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au HJ et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007; 357: 2040–2048.
5. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337–345.
6. Lievre A, Bachet JB, Boige V, Cayre A, Le Corre D, Buc E et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008; 26: 374–379.
7. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008; 359: 1757–1765.
8. Kandasamy K, Mohan SS, Raju R, Keerthikumar S, Kumar GS, Venugopal AK et al. NetPath: a public resource of curated signal transduction pathways. Genome Biol 2010; 11: R3.
9. De Roock W, De Vriendt V, Normanno N, Ciardiello F, Tejpar S. KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. Lancet Oncol 2011; 12: 594–603.
10. Laurent-Puig P, Cayre A, Manceau G, Buc E, Bachet JB, Lecomte T et al. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol 2009; 27: 5924–5930.
11. Shia J, Klimstra DS, Li AR, Qin J, Saltz L, Teruya-Feldstein J et al. Epidermal growth factor receptor expression and gene amplification in colorectal carcinoma: an immunohistochemical and chromogenic in situ hybridization study. Modern Pathol 2005; 18: 1350–1356.
12. Chung KY, Shia J, Kemeny NE, Shah M, Schwartz GK, Tse A et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 2005; 23: 1803–1810.
13. Saltz LB, Meropol NJ, Loehrer PJ Sr, Needle MN, Kopit J, Mayer RJ. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004; 22: 1201–1208.
14. Tsuchihashi Z, Khambata-Ford S, Hanna N, Janne PA. Responsiveness to cetux-imab without mutations in EGFR. N Engl J Med 2005; 353: 208–209.
15. Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 2003; 21: 2787–2799.
16. Balko JM, Black EP. A gene expression predictor of response to EGFR-targeted therapy stratifies progression-free survival to cetuximab in KRAS wild-type metastatic colorectal cancer. BMC cancer 2009; 9: 145.
17. Khambata-Ford S, Garrett CR, Meropol NJ, Basik M, Harbison CT, Wu S et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 2007; 25: 3230–3237.
18. Pentheroudakis G, Kotoula V, De Roock W, Kouvatseas G, Papakostas P, Makatsoris T et al. Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes. BMC cancer 2013; 13: 49.
19. Jhawer M, Goel S, Wilson AJ, Montagna C, Ling YH, Byun DS et al. PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab. Cancer Res 2008; 68: 1953–1961.
20. Buzdin AA, Zhavoronkov AA, Korzinkin MB, Venkova LS, Zenin AA, Smirnov PY et al. Oncofinder, a new method for the analysis of intracellular signaling pathway activation using transcriptomic data. Front Genet 2014; 5: 55.
21. Buzdin AA, Zhavoronkov A, Korzinkin M, Roumiantsev SA, Aliper AM, Venkova LS et al. The OncoFinder algorithm for minimizing the errors introduced by the high-throughput methods of transcriptome analysis. Front Mol Biosci 2014; 1.
22. Borisov NM, Terekhanova NV, Aliper AM, Venkova LS, Smirnov PY, Roumiantsev S et al. Signaling pathway activation profiles make better markers of cancer than expression of individual genes. Oncotarget 2014; 5: 10198–10205.
23. Garber K. Personal mouse colonies give hope for pancreatic cancer patients. J Natl Cancer Inst 2007; 99: 105–107.
24. Morelli MP, Calvo E, Ordonez E, Wick MJ, Viqueira BR, Lopez-Casas PP et al. Prioritizing phase I treatment options through preclinical testing on personalized tumorgraft. J Clin Oncol 2012; 30: e45–e48.
25. Hidalgo M, Bruckheimer E, Rajeshkumar NV, Garrido-Laguna I, De Oliveira E, Rubio-Viqueira B et al. A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer. Mol Cancer Ther 2011; 10: 1311–1316.
26. Rubio-Viqueira B, Jimeno A, Cusatis G, Zhang X, Iacobuzio-Donahue C, Karikari C et al. An in vivo platform for translational drug development in pancreatic cancer. Clin Cancer Res 2006; 12: 4652–4661.
27. Stebbing J, Paz K, Schwartz GK, Wexler LH, Maki R, Pollock RE et al. Patient-derived xenografts for individualized care in advanced sarcoma. Cancer 2014; 120: 2006–2015.
28. Edgar R, Domrachev M, Lash AE. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res 2002; 30: 207–210.
29. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S et al. Bio-conductor: open software development for computational biology and bioinfor-matics. Genome Biol 2004; 5: R80.
30. Gautier L, Cope L, Bolstad BM, Irizarry RA. affy-analysis of Affymetrix GeneChip data at the probe level. Bioinformatics 2004; 20: 307–315.
31. Dai C, Liu J. Inducing pairwise gene interactions from time-series data by EDA based bayesian network. Conf Proc IEEE Eng Med Bio Soc 2005; 7: 7746–7749.
32. Subramanian J, Simon R. Gene expression-based prognostic signatures in lung cancer: ready for clinical use? J Natl Cancer Inst 2010; 102: 464–474.
33. Lezhnina K, Kovalchuk O, Zhavoronkov AA, Korzinkin MB, Zabolotneva AA, She-gay PV et al. Novel robust biomarkers for human bladder cancer based on activation of intracellular signaling pathways. Oncotarget 2014; 5: 9022–9032.
34. Sparks AB, Morin PJ, Vogelstein B, Kinzler KW. Mutational analysis of the APC/beta-catenin/Tcf pathway in colorectal cancer. Cancer Res 1998; 58: 1130–1134.
35. Horst D, Chen J, Morikawa T, Ogino S, Kirchner T, Shivdasani RA. Differential WNT activity in colorectal cancer confers limited tumorigenic potential and is regulated by MAPK signaling. Cancer Res 2012; 72: 1547–1556.
36. Baker SJ, Preisinger AC, Jessup JM, Paraskeva C, Markowitz S, Willson JK et al. p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis. Cancer Res 1990; 50: 7717–7722.
37. Liao X, Lochhead P, Nishihara R, Morikawa T, Kuchiba A, Yamauchi M et al. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med 2012; 367: 1596–1606.
38. O'Hara RJ, Greenman J, MacDonald AW, Gaskell KM, Topping KP, Duthie GS et al. Advanced colorectal cancer is associated with impaired interleukin 12 and enhanced interleukin 10 production. Clin Cancer Res 1998; 4: 1943–1948.
39. Galizia G, Lieto E, De Vita F, Romano C, Orditura M, Castellano P et al. Circulating levels of interleukin-10 and interleukin-6 in gastric and colon cancer patients before and after surgery: relationship with radicality and outcome. J Interferon Cytokine Res 2002; 22: 473–482.
40. Galizia G, Orditura M, Romano C, Lieto E, Castellano P, Pelosio L et al. Prognostic significance of circulating IL-10 and IL-6 serum levels in colon cancer patients undergoing surgery. Clin Immunol 2002; 102: 169–178.
41. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335–2342.
42. Cassano A, Bagala C, Battelli C, Schinzari G, Quirino M, Ratto C et al. Expression of vascular endothelial growth factor, mitogen-activated protein kinase and p53 in human colorectal cancer. Anticancer Res 2002; 22: 2179–2184.
43. Yamaguchi T, Bando H, Mori T, Takahashi K, Matsumoto H, Yasutome M et al. Overexpression of soluble vascular endothelial growth factor receptor 1 in col-orectal cancer: Association with progression and prognosis. Cancer Sci 2007; 98: 405–410.
44. Poindessous V, Ouaret D, El Ouadrani K, Battistella A, Megalophonos VF, Kamsu-Kom N et al. EGFR-and VEGF(R)-targeted small molecules show synergistic activity in colorectal cancer models refractory to combinations of monoclonal antibodies. Clin Cancer Res 2011; 17: 6522–6530.
45. Tabernero J. The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents. Mol Cancer Res 2007; 5: 203–220.
46. Karapetis CS, Jonker D, Daneshmand M, Hanson JE, O'Callaghan CJ, Marginean C et al. PIK3CA, BRAF, and PTEN status and benefit from cetuximab in the treatment of advanced colorectal cancer--results from NCIC CTG/AGITG CO.17. Clin Cancer Res 2014; 20: 744–753.
47. Wu S, Gan Y, Wang X, Liu J, Li M, Tang Y. PIK3CA mutation is associated with poor survival among patients with metastatic colorectal cancer following anti-EGFR monoclonal antibody therapy: a meta-analysis. J Cancer Res Clin Oncol 2013; 139: 891–900.
48. De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2010; 11: 753–762.
49. Zhu CQ, da Cunha Santos G, Ding K, Sakurada A, Cutz JC, Liu N et al. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 2008; 26: 4268–4275.
50. Morgillo F, Woo JK, Kim ES, Hong WK, Lee HY. Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of sur-vivin expression counteract the antitumor action of erlotinib. Cancer Res 2006; 66: 10100–10111.
51. van der Veeken J, Oliveira S, Schiffelers RM, Storm G, van Bergen En Henegouwen PM, Roovers RC. Crosstalk between epidermal growth factor receptor-and insulin-like growth factor-1 receptor signaling: implications for cancer therapy. Curr Cancer Drug Targets 2009; 9: 748–760.
52. He H, Levitzki A, Zhu HJ, Walker F, Burgess A, Maruta H. Platelet-derived growth factor requires epidermal growth factor receptor to activate p21-activated kinase family kinases. The Journal of biological chemistry 2001; 276: 26741–26744.
53. Saito Y, Haendeler J, Hojo Y, Yamamoto K, Berk BC. Receptor heterodimerization: essential mechanism for platelet-derived growth factor-induced epidermal growth factor receptor transactivation. Mol Cell Biol 2001; 21: 6387–6394.
54. Ware KE, Marshall ME, Heasley LR, Marek L, Hinz TK, Hercule P et al. Rapidly acquired resistance to EGFR tyrosine kinase inhibitors in NSCLC cell lines through de-repression of FGFR2 and FGFR3 expression. PLoS ONE 5: e14117.
55. Singleton KR, Kim J, Hinz TK, Marek LA, Casas-Selves M, Hatheway C et al. A receptor tyrosine kinase network composed of fibroblast growth factor receptors, epidermal growth factor receptor, v-erb-b2 erythroblastic leukemia viral onco-gene homolog 2, and hepatocyte growth factor receptor drives growth and survival of head and neck squamous carcinoma cell lines. Mol Pharmacol 83: 882–893.
56. Larsen AK, Ouaret D, El Ouadrani K, Petitprez A. Targeting EGFR and VEGF(R) pathway cross-talk in tumor survival and angiogenesis. Pharmacol Ther 131: 80–90.
57. Lichtenberger BM, Tan PK, Niederleithner H, Ferrara N, Petzelbauer P, Sibilia M. Autocrine VEGF signaling synergizes with EGFR in tumor cells to promote epi-thelial cancer development. Cell 140: 268–279.
58. Saridaki Z, Weidhaas JB, Lenz HJ, Laurent-Puig P, Jacobs B, De Schutter J et al. A let-7 microRNA-binding site polymorphism in KRAS predicts improved outcome in patients with metastatic colorectal cancer treated with salvage cetuximab/ panitumumab monotherapy. Clin Cancer Res 2014; 20: 4499–4510.
59. Luo X, Burwinkel B, Tao S, Brenner H. MicroRNA signatures: novel biomarker for colorectal cancer? Cancer Epidemiol, Biomarker Prev 2011; 20: 1272–1286.
60. Cummins JM, He Y, Leary RJ, Pagliarini R, Diaz LA Jr, Sjoblom T et al. The colorectal microRNAome. Proc Natl Acad Sci USA 2006; 103: 3687–3692.
61. Cappuzzo F, Sacconi A, Landi L, Ludovini V, Biagioni F, D'Incecco A et al. MicroRNA signature in metastatic colorectal cancer patients treated with anti-EGFR mono-clonal antibodies. Clin Colorect Cancer 2014; 13: 37–45 e34.
62. Ruzzo A, Graziano F, Vincenzi B, Canestrari E, Perrone G, Galluccio N et al. High let-7a microRNA levels in KRAS-mutated colorectal carcinomas may rescue anti-EGFR therapy effects in patients with chemotherapy-refractory metastatic disease. The Oncologist 2012; 17: 823–829.